2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 794

Negative Temporal Artery Biopsies: Comparison between Biopsy-Negative GCA and Non-GCA Patients
Abstract Number: 795

Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Abstract Number: 796

Presentation and Outcome of Large-Vessel Vasculitis Diagnosed between 50 and 60 Years: Case-Control Study Based on 183 Cases
Abstract Number: 797

Temporal Arteritis Revealing Antineutrophil Cytoplasmic Antibody–Associated Vasculitides: A Retrospective Study of 50 Cases
Abstract Number: 798

Altered Phenotype of Platelets and Neutrophils Toward Neutrophil-Platelet Interaction in Circulation of Small and Large Vessel Vasuculitis
Abstract Number: 799

Acetylcholinesterase Is Highly Expressed in the Inflamed Vessel Wall of Patients with Giant Cell Arteritis
Abstract Number: 800

Measurement of Serum Cytokines during the Apparent Remission State of Takayasu Arteritis – What Do Cytokines Tell Us?
Abstract Number: 801

PET-CT Findings and Clinical Outcomes in Takayasu Arteritis – Does 18F-Fluorodeoxyglucose Uptake in Arteries Predict Relapses?
Abstract Number: 802

Sensorineural Hearing Loss in Takayasu’s Arteritis
Abstract Number: 803

Cardiovascular Risk Factors and Comorbid Diseases in Takayasu’s Arteritis
Abstract Number: 804

The Efficacy and Safety of the Anti-IL-6 Receptor Antibody Tocilizumab for Polymyalgia Rheumatica Patients with Resistance or Intolerance to Glucocorticoids and Methotrexate
Abstract Number: 805

Serological Immune-Inflammatory Markers of the First RCT about Tocilizumab to Treat Giant Cell Arteritis
Abstract Number: 806

Epidemiological Study of Giant Cell Arteritis Using a Japanese Administrative Database
Abstract Number: 807

B Cells in Giant Cell Arteritis: a Novel Target for Treatment?
Abstract Number: 808

Assessing the Possible Link between Varicella Zoster Virus and Giant Cell Arteritis Using Clinical Assessment, Serology and Biopsy Antigen Detection – Interim Results from the Giant Cell Arteritis and PET Scan (GAPS) Cohort

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].